Investor Relations. We are a clinical-stage biopharmaceutical company focused ... LPCN 2101 for the potential treatment of epilepsy and LPCN 1148, a novel ...
Investor Relations. We are a clinical-stage ... (NASDAQ: LPCN), a biopharmaceutical company... Nov 13, 2023. Lipocine Releases Late Breaking Presentation on LPCN ...
People also ask
Is LPCN a buy?
What is lipocine used for?
Nov 8, 2023 · Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN1154, for rapid relief of ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
Mar 7, 2024 · (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for ...
Get the latest insights on Lipocine Inc. Common Stock (LPCN) with press releases and corporate news to help you in your trading and investing decisions.
Get the latest Lipocine Inc. (LPCN) stock news and headlines to help you in your trading and investing decisions.
Discover insights from Lipocine Inc.'s annual reports and investor relations material with Quarterlytics' easy-to-use platform. Identify trends, assess risk ...
Investor Relations URL, https://ir.lipocine.com/ ; HQ State/Province, Utah ; Sector, Health Care ; Industry, Pharmaceuticals ; Equity Style, Small Cap/Value.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports ( ...